Because CYP1A2 mediates ~95% of caffeine metabolism, any potent CYP1A2 inhibitor dramatically increases caffeine exposure. Fluvoxamine is the most clinically significant: standard therapeutic doses increase caffeine half-life from approximately 5 hours to 31 hours, with total clearance reduced 5-foldsupported
Fluvoxamine co-administration impairs caffeine clearance and prolongs elimination half-life via CYP1A2 inhibition. pmid:16236038
Abuse potential is low — caffeine does not produce the behavioral reinforcement profile of classic drugs of abuse, though it acts as a weak reinforcer.supported
Covers adenosine antagonism, dopaminergic effects, reinforcement, withdrawal, tolerance. pmid:10049999
The estimated human LD50 is approximately 150–200 mg/kg body weight — roughly 10.5–14 g for a 70 kg adult, equivalent to approximately 80–100 cups of brewed coffeesupported
LD50 stated as 150-200 mg/kg; lethal plasma levels ~80-100 ug/mL (~10g ingestion). j.ajem.2019.09.018
Claim in safety — inconclusiveinconclusiveworking →
The caffeine overdose toxidrome progresses dose-dependently:supported
Tachyarrhythmias, hemodynamic instability. Pre-dialysis caffeine level 254 ug/mL. j.ajem.2019.09.018
The caffeine overdose toxidrome progresses dose-dependently:supported
Review of caffeine mechanisms... use, abuse, dependence, intoxication, lethal effects. 1570159x13666141210215655
Kohl et al. reported a 39-year-old male who intentionally ingested 50 g of caffeine (pre-dialysis plasma level: 254 ug/mL) — approximately 2.5 times the lethal plasma thresholdsupported
Case report: 39-year-old male ingested 50g caffeine. Lethal plasma levels ~80-100 ug/mL. Pre-dialysis caffeine level 254 ug/mL. j.ajem.2019.09.018
Claim in safety — inconclusiveinconclusiveworking →
Caffeine induces cerebral vasoconstriction — a property exploited therapeutically in headache and migraine treatmentsupported
Caffeine (as adenosine receptor antagonist) inhibits adenosine-mediated relaxation in middle meningeal artery, providing molecular mechanism for caffeine's utility as cranial pain/headache adjuvant. journal.pone.0108782
At high doses, particularly in the context of energy drink consumption, caffeine can provoke tachyarrhythmias via cardiac calcium overload and catecholamine surgesupported
Two case reports of life-threatening ventricular arrhythmias in young patients after energy drink consumption. jce.13210
Martinez et al. documented sudden cardiac arrest in young adults temporally associated with energy drink consumption.supported
Documents cases of sudden cardiac arrest in temporal proximity to consumption of energy drinks. j.hrthm.2024.02.018
Claim in safety — inconclusiveinconclusiveworking →
Greenwood et al.'s meta-analysis (60 publications) quantified dose-dependent pregnancy risks per 100 mg daily caffeine increment:supported
Meta-analysis of 60 publications: per 100mg caffeine increment associated with 14% increased spontaneous abortion risk, 19% stillbirth, 7% low birth weight, 10% SGA. s10654-014-9944-x
Current guidelines recommend <=200 mg/day during pregnancy.supported
For pregnant women: up to 200mg/day safe. j.efsa.2015.4102
Caffeine has dose-dependent anxiogenic properties:supported
High doses can induce psychotic/manic symptoms. Panic disorder patients particularly sensitive to anxiogenic effects. jad-2010-1378
Caffeine has dose-dependent anxiogenic properties:supported
Systematic review and meta-analysis of caffeine's anxiogenic and panicogenic effects in panic disorder patients. Quantifies magnitude and dose-response relationships. j.genhosppsych.2021.11.005
Very high doses: Rare psychotic or manic symptoms have been reportedsupported
High doses can induce psychotic/manic symptoms. jad-2010-1378
Patients with panic disorder are particularly sensitive — caffeine challenge reliably provokes panic attacks in this populationsupported
Systematic review and meta-analysis of caffeine's anxiogenic and panicogenic effects in panic disorder patients. j.genhosppsych.2021.11.005
The anxiogenic threshold is influenced by ADORA2A polymorphism (A2A receptor gene variant), with certain genotypes showing heightened vulnerability.supported
A2A receptor polymorphism influences anxiety threshold. jad-2010-1378
Caffeine withdrawal symptoms can closely mimic psychiatric disorders (anxiety, depression, cognitive impairment), representing a documented source of clinical misdiagnosis.supported
Symptoms: headache, fatigue, irritability, mood changes. Regular use produces physical and psychological dependence. nu16183048
Tolerance develops to many of caffeine's effects with regular use, particularly psychomotor/locomotor stimulationsupported
Covers adenosine antagonism, dopaminergic effects, reinforcement, withdrawal, tolerance. pmid:10049999
The molecular mechanism involves upregulation of adenosine receptors and functional adaptation of A1-A2A heteromers in the striatumsupported
Caffeine acts on A1-A2A heteromers; chronic caffeine leads to tolerance through modifications in heteromer function. jneurosci.3574-05.2006
Tolerance to wakefulness-promoting effects is incomplete — caffeine remains wake-promoting even in chronic users, though the effect is blunted compared to the caffeine-naive state.supported
Daily caffeine intake and withdrawal affect circadian rhythms and wake-promotion. Evidence for adaptation after repeated intake. j.pnpbp.2019.109851
Caffeine dependence is recognized in the DSM-5 as Caffeine Use Disorder (designated for further study), with Caffeine Withdrawal as a fully diagnosable conditionsupported
Review of caffeine withdrawal as DSM-5 recognized condition. nu16183048
Strain et al. established the caffeine dependence syndrome using DSM-IV criteria in 1994supported
Assessment of caffeine dependence syndrome using DSM-IV generic criteria for substance dependence. Landmark JAMA paper establishing caffeine dependence syndrome. pmid:8089887
Juliano et al. characterized 94 treatment-seeking individuals: 93% met DSM-IV substance dependence criteria, with mean daily intake of 548 mg; withdrawal (96%), persistent desire or unsuccessful efforts to control use (89%), and continued use despite problems (87%) were the most prevalent criteria.supported
94 subjects seeking caffeine dependence treatment; mean 548 mg/day intake; 93% met DSM-IV substance dependence criteria. Withdrawal (96%), persistent desire to control use (89%), use despite problems (87%). a0027246
Lethal plasma concentration is approximately 80–100 ug/mL.supported
Lethal plasma levels ~80-100 ug/mL (~10g ingestion). j.ajem.2019.09.018
Caffeine withdrawal syndrome (DSM-5 recognized):supported
Review of caffeine withdrawal as DSM-5 recognized condition. Symptoms: headache, fatigue, irritability, mood changes. nu16183048
Mechanism: Withdrawal headache results from rebound cerebral vasodilation following cessation of caffeine-mediated vasoconstrictionsupported
Caffeine (as adenosine receptor antagonist) inhibits adenosine-mediated relaxation in middle meningeal artery, providing molecular mechanism for caffeine's utility as cranial pain/headache adjuvant. journal.pone.0108782
Because CYP1A2 mediates ~95% of caffeine metabolism, any potent CYP1A2 inhibitor dramatically increases caffeine exposure. Fluvoxamine is the most clinically significant: standard therapeutic doses increase caffeine half-life from approximately 5 hours to 31 hours, with total clearance reduced 5-foldsupported
Fluvoxamine 50-100mg/day increases caffeine half-life from 5h to 31h and reduces total clearance from 107 to 21 ml/min. pmid:8807660
Even low-dose fluvoxamine (10–20 mg/day) substantially inhibits caffeine metabolismsupported
Even low therapeutic doses of fluvoxamine significantly inhibit CYP1A2 activity as measured by caffeine metabolic ratio. pmid:11907488
Claim in safety — inconclusiveinconclusiveworking →
CYP1A2 inducers — principally tobacco smoke (via polycyclic aromatic hydrocarbons) — accelerate caffeine clearance by 40–65%supported
Polycyclic aromatic hydrocarbons in tobacco smoke induce CYP1A2, leading to faster caffeine clearance. pmid:10427467
Claim in safety — inconclusiveinconclusiveworking →
Vanattou-Saifoudine et al. conducted the most comprehensive review of caffeine-psychostimulant interactions, finding that caffeine profoundly enhances MDMA toxicity in preclinical models: dramatically increased hyperthermia, tachycardia, cardiovascular toxicity, mortality, and enhanced long-term serotonergic neurotoxicitysupported
Caffeine co-administration profoundly enhances acute MDMA toxicity: hyperthermia, tachycardia, increased mortality in rats. Enhances long-term serotonergic neurotoxicity of MDMA. j.1476-5381.2012.02065.x
Similar enhancement of toxicity applies to cocaine, d-amphetamine, and ephedrine combinations via the same adenosine/PDE pathways.supported
Same mechanism implicated with cocaine, d-amphetamine, and ephedrine. Mechanism: MDMA-dopamine release + caffeine adenosine antagonism + PDE inhibition. j.1476-5381.2012.02065.x
Caffeine partially masks subjective alcohol intoxication but does not reduce blood alcohol concentration or actual psychomotor impairmentsupported
Energy drink + alcohol study: caffeine masks subjective intoxication but does not reduce blood alcohol or objective performance impairment. s00213-012-2677-1
Panic disorder and anxiety disorders: Caffeine reliably provokes panic attacks in patients with panic disorder and exacerbates generalized anxietysupported
Systematic review and meta-analysis of caffeine's anxiogenic and panicogenic effects in panic disorder patients. j.genhosppsych.2021.11.005
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Pregnancy: Dose-dependent risks for spontaneous abortion, stillbirth, and low birth weight with no identifiable safe threshold below 200 mg/day.supported
Meta-analysis of 60 publications: per 100mg caffeine increment associated with 14% increased spontaneous abortion risk, 19% stillbirth, 7% low birth weight. No identifiable threshold below which associations are absent. s10654-014-9944-x
CYP1A2 inhibitor co-administration: Patients on fluvoxamine, ciprofloxacin, or other potent CYP1A2 inhibitors face dramatically elevated caffeine exposure and should reduce intake proportionally.supported
Warns of caffeine intoxication risk during fluvoxamine treatment. Fluvoxamine 50-100mg/day increases caffeine half-life from 5h to 31h. pmid:8807660
Claim in safety — inconclusiveinconclusiveworking →